CAC
BLACR

Cowen and Company’s Bellevue Life Sciences Acquisition Corp. Rights BLACR Stock Holding History

Cowen and Company’s Portfolio BLACR Stock Details BLACR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-323,252
Closed -$35.3K – 488
2024
Q3 		$35.3K Buy
323,252
+73,397
+29% +$9.72K ﹤0.01% 378
2024
Q2 		$25K Buy
+249,855
New +$34.1K ﹤0.01% 380
2023
Q2 		– Sell
-125,100
Closed -$22.5K – 636
2023
Q1 		$22.5K Buy
+125,100
New +$19.4K ﹤0.01% 295

Other funds holding BLACR

HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
HCI
Harraden Circle Investments New York $499M AUM 24.03% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
ASM
ATW SPAC Management New York $79.2M AUM 10.67% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
Walleye Trading
Walleye Trading New York $60B AUM 42.19% 1-Year Est. Return

Cowen and Company's BLACR Position: Q4 2024 in Review

Cowen and Company sold out of Bellevue Life Sciences Acquisition Corp. Rights (BLACR) in Q4 2024, closing a stake of 323,252 shares — an estimated $35.3K sold.

Cowen and Company first reported a position in BLACR in Q1 2023 and held it in 3 quarters. The position peaked at $35.3K in Q3 2024. 28 funds tracked by Wall St. Rank hold BLACR as of Q4 2024.

  • Cowen and Company reported no remaining Bellevue Life Sciences Acquisition Corp. Rights position as of Q4 2024 after selling out during the quarter.
  • Cowen and Company sold 323,252 Bellevue Life Sciences Acquisition Corp. Rights shares in Q4 2024, an estimated $35.3K.
  • Cowen and Company first reported a position in Bellevue Life Sciences Acquisition Corp. Rights in Q1 2023 and held it in 3 quarters.
  • Cowen and Company's Bellevue Life Sciences Acquisition Corp. Rights position peaked at $35.3K in Q3 2024.
  • 28 funds tracked by Wall St. Rank held Bellevue Life Sciences Acquisition Corp. Rights as of Q4 2024.

Based on Cowen and Company's 13F filing for Q4 2024.